Arrowstreet Capital Limited Partnership Trims Holdings in Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Arrowstreet Capital cut its Supernus Pharmaceuticals stake by 95.9% in the first quarter, selling 176,093 shares and retaining 7,595 shares valued at approximately $393,000.
• Analyst sentiment is mixed: four analysts rate SUPN a Buy, two rate it Hold, and one rates it Sell. The overall consensus is Hold, with an average price target of $62.83.
• Supernus shares opened at $47.64, compared with a 52-week range of $40.26 to $59.68, while the company continues to focus on CNS therapies including Trokendi XR, Oxtellar XR, and Qelbree.

Arrowstreet Capital Limited Partnership lowered its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 95.9% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 7,595 shares of the specialty pharmaceutical company's stock after selling 176,093 shares during the quarter. Arrowstreet Capital Limited Partnership's holdings in Supernus Pharmaceuticals were worth $393,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in SUPN. Rockefeller Capital Management L.P. increased its position in Supernus Pharmaceuticals by 354.8% during the 4th quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company's stock valued at $42,000 after purchasing an additional 660 shares during the period. Torren Management LLC purchased a new stake in shares of Supernus Pharmaceuticals in the 4th quarter worth about $49,000. EverSource Wealth Advisors LLC purchased a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter worth about $51,000. Hantz Financial Services Inc. boosted its stake in shares of Supernus Pharmaceuticals by 73.3% during the 4th quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company's stock valued at $54,000 after purchasing an additional 458 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter valued at about $55,000.

Analyst Upgrades and Downgrades

SUPN has been the subject of several research reports. Wall Street Zen lowered Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Zacks Research raised Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Monday, April 27th. Finally, Cantor Fitzgerald increased their price objective on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an "overweight" rating in a report on Thursday, July 9th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $62.83.

Supernus Pharmaceuticals Stock Performance

Shares of Supernus Pharmaceuticals stock opened at $47.64 on Friday. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $40.26 and a fifty-two week high of $59.68. The company has a market capitalization of $2.77 billion, a P/E ratio of -24.81, a P/E/G ratio of 0.76 and a beta of 0.56. The company has a fifty day moving average of $46.17 and a 200 day moving average of $48.93.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company's marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source